Prescription drug prices are a serious burden in America, and perhaps the chief modern example of why good intentions do not always equal solutions. Take the newly introduced Medication Affordability and Patent Integrity Act, sponsored by Sens. Maggie Hassan (D-NH) and Josh Hawley (R-MO).Conceptually, it’s a modest transparency measure aimed at preventing contradictory statements to regulators. The bill would impose new certification and disclosure mandates on drug innovators when they interact with the FDA and U.S. Patent and Trademark Office.That’s great in theory. But in practice, it would treat patents filed throughout a lengthy and dynamic process as evidence of earlier gamesmanship. From an economic standpoint, that’s a backward misunderstanding of how biomedical innovation works. It risks injecting uncertainty into the system, inviting collateral litigation, and weakening the incentives that help bring new cures and treatments to patients.
HATE BIG PHARMA ALL YOU LIKE, IT STILL MIGHT SAVE YOUR LIFE
Drug development is not a static event. It is a long, risky, and cumulative process. Medicines often receive initial FDA approval while research and patent-filing continue. New formulations, dosing regimens, delivery mechanisms, manufacturing improvements, and better scientific understanding can all emerge later. The improvements matter greatly for patients and may qualify as genuine inventions of their own.
